6/30/23, 2:17 AM TOGETHER (ivermectin) Pathway Feedback Search Clinical Topics Home Studies TOGETHER (ivermectin) TOGETHER (ivermectin) Disease COVID 19 infection Trial question What is the role of early treatment with ivermectin in patients with COVID-19? Study design Multi-center Double blinded RCT Population Characteristics of study participants 58.0% female N = 1358 42.0% male 1358 patients (791 female, 567 male) Inclusion criteria: adult patients who had symptoms of COVID-19 for up to 7 days with one risk factor for disease progression Key exclusion criteria: diagnostic test for negative COVID-19 associated with acute flu symptoms; requirement of hospitalization due to COVID-19; acute respiratory symptoms due to other causes; dyspnea secondary to other acute and chronic respiratory causes or infections Interventions N=679 ivermectin (400 g/kg of body weight once daily for 3 days) N=679 placebo (matching placebo for 3 days) Primary outcome https://web.pathway.md/studies/rec9O1z2zpUFslj6a 1/2 6/30/23, 2:17 AM TOGETHER (ivermectin) Pathway Hospitalization due to COVID-19 or emergency department visits due to clinical worsening of COVID-19 at 28 days 16.3 % 16.3 14.7 12.2 % 8.2 % 4.1 % No significant difference 0.0 % Ivermectin Placebo No significant difference in hospitalization due to COVID-19 or emergency department visits due to clinical worsening of COVID-19 at 28 days (14.7% vs. 16.3%; RR 0.9, 95% CI 0.7 to 1.16) Secondary outcomes No significant difference in viral clearance at day 7 (25.4% vs. 25.5%; RR 1, 95% CI 0.68 to 1.46) No significant difference in hospitalization for any cause (11.6% vs. 14%; RR 0.83, 95% CI 0.63 to 1.1) No significant difference in death (3.1% vs. 3.5%; RR 0.88, 95% CI 0.49 to 1.55) Safety outcomes No significant difference in adverse events. Conclusion In adult patients who had symptoms of COVID-19 for up to 7 days with one risk factor for disease progression, ivermectin was not superior to placebo with respect to hospitalization due to COVID-19 or emergency department visits due to clinical worsening of COVID-19 at 28 days. Reference Gilmar Reis, Eduardo A S M Silva, Daniela C M Silva et al. Effect of Early Treatment with Ivermectin among Patients with Covid-19. N Engl J Med. 2022 May 5;386(18):1721-1731. Open reference URL https://web.pathway.md/studies/rec9O1z2zpUFslj6a 2/2